Studies have recently shown that tumor immunotherapy, like immune checkpoint blockade (ICB), especially programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1), could be used for PD-L1 immune positive and platinum ineligible patients, as well as newly for those who are responding to platinum as maintenance therapy, it could also invigorate antitumor immune response and prolong survival of advanced MIBC patients resistant to chemotherapy, which revolutionized the therapeutic landscape (5, 6). The gene discussed is PDCD1; the disease is neoplasm.